No Data
HK stocks anomaly | Jun Sheng Tai Medicine-B (02511) plunged 41%, removed from the Hong Kong Stock Connect, with a total market value evaporating over 6 billion Hong Kong dollars.
Junshengtai Medicine-B (02511) plummeted by 41%, hitting a new low of 0.72 Hong Kong dollars. The current market cap is less than 0.5 billion Hong Kong dollars, evaporating over 6 billion Hong Kong dollars from its peak value.
Jinshengtai Medicine - B [02511] is now trading at HK$1.29, with a 10.26% increase.
As of 14:29, Kun Shengtai Pharmaceuticals - B [02511] reported HK$1.29, up HK$0.12 or 10.26% from the previous closing price of HK$1.17, with a turnover of HK$6.3895 million. The highest price today is HK$1.29, and the lowest price is HK$1.12. Based on yesterday's closing price, the 10-day average price is HK$6.16, and the 50-day average price is HK$5.82. The current price-earning ratio is -1.35 times, and the 14-day relative strength index is 50.98.
Junshengtai Medicine - B (02511) fell by 77.50%, now trading at 1.210 yuan, hitting a new 52-week low.
As of 11:45, Junshengtai Medicine - B (02511) fell 77.50% compared to the closing price yesterday, with a current price of 1.210 yuan, hitting a new 52-week low; the volume was 2.3835 million shares, with a turnover of 2.8441 million Hong Kong dollars.
Junshengtai Medicine-B (02511.HK) announced its interim performance: the loss narrowed to 0.211 billion yuan, and 2 candidate products are in the clinical stage.
On August 28th, GeLonghui announced its interim performance. In the first half of 2024, the company had other income and profits of 38.3 million yuan, a year-on-year increase of 68.7%. Research and development costs were 0.202 billion yuan, an increase of 68.2%. The increase was mainly due to an increase in third-party contracting expenses of approximately 70.8 million yuan and an increase in expenses under the employee long-term incentive plan of approximately 12 million yuan. The loss was 0.211 billion yuan, compared to 5.497 billion yuan in the first half of 2023. As of June 30, 2024, the company's current assets.
HIGHTIDE-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
Kun Shengtai Medicine -B (02511.HK) held a board of directors meeting on August 28 to review and approve its interim performance.
Junshengtai Pharmaceutical-B (02511.HK) announced on August 14 that the board of directors meeting will be held on August 28, 2024 (Wednesday) to deliberate and approve the company and its subsidiary's mid-term performance for the six months ending on June 30, 2024, and handle other matters, including the release of the performance report.
No Data
No Data